Jefferies Reaffirms Their Hold Rating on Genomic Health

By Austin Angelo

In a report released today, Eun Yang from Jefferies reiterated a Hold rating on Genomic Health (NASDAQ: GHDX), with a price target of $33. The company’s shares closed last Friday at $31.92.

According to, Yang is a 3-star analyst with an average return of 0.8% and a 45.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Genomic Health has an analyst consensus of Moderate Buy, with a price target consensus of $34.50.

The company has a one year high of $33.96 and a one year low of $24.81. Currently, Genomic Health has an average volume of 120K.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GHDX in relation to earlier this year. Last month, Steven Shak, the EVP of R&D of GHDX sold 10,000 shares for a total of $254,200.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. Its uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott and Steven Shak in August 2000 and is headquartered in Redwood City, CA.